Video

Dr. Kris Discusses EGFR Mutation Testing

Author(s):

Mark G. Kris, MD, FASCO

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses EGFR mutation testing for patients with lung cancer, at the 2010 ASCO Annual Meeting.

Related Videos
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Ritu Salani, MD
Aaron Gerds, MD
Maximilian Stahl, MD
Abhirami Vivekanandarajah, MD
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Lung Cancer
December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC